Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $497,560 | $323,536 | $180,386 | $231,549 |
| - Cash | $71,621 | $67,449 | $121,966 | $67,271 |
| + Debt | $271,447 | $229,191 | $198,057 | $88,067 |
| Enterprise Value | $697,386 | $485,278 | $256,477 | $252,345 |
| Revenue | $203,070 | $163,914 | $110,248 | $49,590 |
| % Growth | 23.9% | 48.7% | 122.3% | – |
| Gross Profit | $166,238 | $135,269 | $87,614 | $36,272 |
| % Margin | 81.9% | 82.5% | 79.5% | 73.1% |
| EBITDA | -$13,994 | -$23,735 | -$69,314 | -$113,666 |
| % Margin | -6.9% | -14.5% | -62.9% | -229.2% |
| Net Income | -$54,836 | -$62,255 | -$94,660 | -$122,725 |
| % Margin | -27% | -38% | -85.9% | -247.5% |
| EPS Diluted | -0.37 | -0.45 | -0.7 | -1.55 |
| % Growth | 17.8% | 35.7% | 54.8% | – |
| Operating Cash Flow | -$36,981 | -$47,023 | -$102,891 | -$102,891 |
| Capital Expenditures | -$868 | -$2,263 | -$524 | -$524 |
| Free Cash Flow | -$37,849 | -$49,286 | -$103,415 | -$103,415 |